+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID05878717

Evaluating Subcutaneous Belimumab with Standard Therapy in Adults with Systemic Sclerosis Associated Interstitial Lung Disease A Randomized, Double-Blind, Placebo-Controlled Phase 23 Trial

Led by GlaxoSmithKline · Updated on 2026-09-08

300

Participants Needed

134

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of belimumab compared to placebo, both given alongside standard therapy, for adults with systemic sclerosis associated interstitial lung disease SSc-ILD. The study aims to assess how belimumab affects lung function and other disease features such as skin thickening and symptoms like fatigue that influence quality of life. Participants will be randomly assigned to receive either belimumab or a placebo, both in addition to their usual therapy. Belimumab is given by subcutaneous injection. The study measures various health outcomes at baseline and after 52 weeks, including lung capacity, skin condition, fatigue, and disease progression. Throughout the study, participants will undergo scans, lung function tests, skin assessments, and questionnaires about symptoms and quality of life. Researchers will monitor adverse events and disease markers to evaluate treatment impact and safety over the 52-week period.

CONDITIONS

Brief Title

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Research Team

U

US GSK Clinical Trials Call Center

E

EU GSK Clinical Trials Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here